Study of DNA repair traits in ovarian cancer patients
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with epithelial ovarian cancer confirmed by pathology
- Your cancer stage is either stage I–II with a BRCA1 or BRCA2 mutation, or stage III–IV
- You are 18 years or older at the time of diagnosis
- Your treatment plan includes platinum-based chemotherapy
- You can sign informed consent and follow the study rules
- You agree to share stored tumor tissue from previous procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This study looks at genetic and other factors that may explain why some people with ovarian cancer respond well to platinum-based chemotherapy for many years, while others do not respond at all. The goal is to better understand these differences to improve future treatments.
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.